A Randomized Comparison of a Sirolimus-eluting Stent with Biodegradable Polymer versus an Everolimus-eluting Stent with a Durable Polymer for Percutaneous Coronary Revascularization Thomas Pilgrim, MD Swiss Cardiovascular Center Bern University Hospital, Switzerland A Meta-Analysis of Biodegradable Polymer DES versus Durable Polymer Sirolimus Eluting Stents Stefanini G et al. Lancet 2011; 378:1940-8 TLR Definite ST BP-DES DP-SES ISAR-TEST 3 17/202 RR (95% CI) 21/202 0·81 (0·44, 1·49) 2 years fup ISAR-TEST 4 ISAR-TEST 3 RR (95% CI) 1/202 2/202 0·50 (0·05, 5·47) 9/1299 9/652 0·50 (0·20, 1·26) 20/857 32/850 0·62 (0·36, 1·08) 2 years fup 168/1299 95/652 0·89 (0·70, 1·12) 3 years fup LEADERS BP-DES DP-SES ISAR-TEST 4 3 years fup 88/857 111/850 0·79 (0·60, 1·02) 4 years fup LEADERS 4 years fup Overall (I-squared = 0·0%, p=0·79) 0·1 0·2 0·5 Favours biodegradable polymer DES 0·84 (0·71, 0·99) 1 2 5 Favours durable polymer SES Overall (I-squared = 0·0%, p=0·92) 0·1 0·2 0·58 (0·37, 0·93) 0·5 Favours biodegradable polymer DES 1 2 5 Favours durable polymer SES Biodegradable Polymer Based DES Platforms Sirolimus – Genous Bioengineered R Stent Biolimus A9 – BioMatrix Nobori, Axxess, XTENT Everolimus - SYNERGY Sirolimus – ORSIRO Myolimus – ELIXIR 100% % Myolimus Released Sirolimus – ISAR TEST 80% 60% 40% 20% 0% 0 3 28 90 Number of Days Orsiro1 Hybrid Sirolimus Eluting Stent System Passive component: PROBIO • Silicon carbide2 layer that encapsulates the stent surface, reducing ion release Active component: BIOlute • PLLA3 bioabsorbable polymer matrix • Sirolimus (1.4 µg/mm2) • Controlled drug release out to 3 months • Asymmetric coating with greater drug dose on abluminal side In vivo drug release in minipig coronary arteries (Ablumial thickness 7.4 µm) 100 Stent platform: PRO-Kinetic Energy • Cobalt Chromium, L-605 • 60 µm struts % Drug Release 90 80 70 60 50 40 30 20 10 0 1 Manufactured and distributed by BIOTRONIK 2 aSiC:H amorphous silicon carbide 3 Poly-L-lactide 0 10 20 30 40 50 60 Time (days) Source: Data on file at BIOTRONIK 70 80 90 100 BIOSCIENCE Trial NCT01443104 Prospective multi-center randomized “all-comers” trial with a non-inferiority design 2100 Patients 1:1 Orsiro® Stent system Xience PRIME® stent Sirolimus-eluting stent with a biodegradable polymer Everolimus-eluting stent with a durable polymer Primary endpoint: Target lesion failure defined as the composite of cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularization at 12 months Inclusion Criteria 1 Age ≥18 years; 2 Symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes including NSTE-ACS and STE-ACS; 3 Presence of one or more coronary artery stenoses >50% in a native coronary artery or a saphenous bypass graft which can be treated with a stent ranging in diameter from 2.25 to 4.0 mm and can be covered with one or multiple stents; 4 No limitation on the number of treated lesions, and vessels, and lesion length Exclusion Criteria 1 Pregnancy; 2 Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Sirolimus, Everolimus or contrast material; 3 Inability to provide informed consent; 4 Currently participating in another trial before reaching first endpoint; 5 Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period Follow-up Clinical follow-up (visit) at 12 months; Telephone follow-up at 30 days, 1, 2, and 5 years Primary Endpoint Target lesion failure (TLF) in the overall population, defined as the composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI) (i.e., Q-wave MI that cannot be attributed to a non-target vessel), clinically driven target lesion revascularization (TLR) and emergent coronary artery bypass grafting (CABG) within 12 months. Secondary Endpoints Clinically indicated and not clinically indicated target lesion revascularization (TLR) at 30 days, 1, 2 and 5 years. Clinically indicated and not clinically indicated target vessel revascularization (TVR) at 30 days, 1, 2, and 5 years. TLF composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI) (i.e., Q-wave MI that cannot be attributed to a non-target vessel), clinically driven target lesion revascularization (TLR) and emergent coronary artery bypass grafting (CABG)at 30 days, 2, and 5 years. Target Vessel Failure (TVF) at 30 days, 1, 2, and 5 years. Cardiac death at 30 days, 1, 2, and 5 years. All deaths (cardiac and non-cardiac) at 30 days, 1, 2, and 5 years. Myocardial infarction (Q-wave and NQWMI) at 30 days, 1, 2, and 5 years. Definite stent thrombosis at 30 days, 1, 2, 3and 5 years. Definite or probable stent thrombosis at 30 days, 1, 2, and 5 years. Device success, lesion success and procedural success (see definitions). Time Schedule Event Type of contact Inclusion/ exclusion Criteria Informed consent Physical examination Medical and Cardiac history Anginal Status CBC, blood chemistry, lipids, CK, CK-MB Troponin 12 lead ECG Medication regimen Adverse event and Severe Adverse Event monitoring Screen Procedur Post -Procedure e to Hospital D/c 30 Days 1 Yr 2 Yrs 5 Yrs Phone Visit Phone Phone X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X Contacts Dr. med. Thomas Pilgrim Invasive Kardiologie, Inselspital Bern thomas.pilgrim@insel.ch 076 548 44 11